It's shaping up to be a tough period for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which a week ago released some disappointing quarterly results that could have a notable impact on how the market views the stock. It wasn't a great result overall - while revenue fell marginally short of analyst estimates at US$2.8b, statutory earnings missed forecasts by an incredible 34%, coming in at just US$2.49 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Vertex Pharmaceuticals after the latest results.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqGS:VRTX Earnings and Revenue Growth May 9th 2025

After the latest results, the 32 analysts covering Vertex Pharmaceuticals are now predicting revenues of US$11.9b in 2025. If met, this would reflect a reasonable 7.5% improvement in revenue compared to the last 12 months. Vertex Pharmaceuticals is also expected to turn profitable, with statutory earnings of US$15.10 per share. In the lead-up to this report, the analysts had been modelling revenues of US$12.0b and earnings per share (EPS) of US$15.73 in 2025. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.

Check out our latest analysis for Vertex Pharmaceuticals

The consensus price target held steady at US$500, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Vertex Pharmaceuticals, with the most bullish analyst valuing it at US$621 and the most bearish at US$330 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Vertex Pharmaceuticals' revenue growth is expected to slow, with the forecast 10% annualised growth rate until the end of 2025 being well below the historical 15% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 17% annually. Factoring in the forecast slowdown in growth, it seems obvious that Vertex Pharmaceuticals is also expected to grow slower than other industry participants.

Story Continues

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Vertex Pharmaceuticals. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$500, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Vertex Pharmaceuticals going out to 2027, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades  for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments